• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Unfinished Business in Preventing Alzheimer Disease.预防阿尔茨海默病的未竟事业。
JAMA Intern Med. 2016 Dec 1;176(12):1739-1740. doi: 10.1001/jamainternmed.2016.6310.
2
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.与患有阿尔茨海默病和轻度认知障碍的医疗保险受益人群相比，有资格参加阿杜卡奴单抗治疗阿尔茨海默病临床试验的参与者的代表性。
JAMA. 2021 Oct 26;326(16):1627-1629. doi: 10.1001/jama.2021.15286.
3
"Recommendations concerning regulatory and legal aspects" contribution to the European task force on disease modifying trials in Alzheimer's disease.“关于监管和法律方面的建议” 对欧洲阿尔茨海默病疾病修饰试验特别工作组的贡献。
J Nutr Health Aging. 2006 Mar-Apr;10(2):139-41.
4
[Clinical trials in AD].[阿尔茨海默病的临床试验]
Rinsho Shinkeigaku. 2010 Nov;50(11):835. doi: 10.5692/clinicalneurol.50.835.
5
"Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.阿杜卡奴单抗的“真实世界”准入取决于临床环境和患者的治疗历程。
J Am Geriatr Soc. 2022 Feb;70(2):626-628. doi: 10.1111/jgs.17530. Epub 2021 Nov 9.
6
Into the darkness of the mind.进入心灵的黑暗之中。
Newsweek. 2003 Dec 8;142(23):90, 92.
7
Donanemab: First Approval.度拉糖肽：首次获批
Drugs. 2024 Oct;84(10):1313-1318. doi: 10.1007/s40265-024-02087-4. Epub 2024 Sep 6.
8
Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.近期获批的阿尔茨海默病药物引发了可能永远无法解答的问题。
JAMA. 2021 Aug 10;326(6):469-472. doi: 10.1001/jama.2021.11558.
9
Rapid drug access and scientific rigour: a delicate balance.快速药物获取与科学严谨性：微妙的平衡。
Lancet Neurol. 2021 Jan;20(1):1. doi: 10.1016/S1474-4422(20)30452-X.
10
Stop Alzheimer's before it starts.在阿尔茨海默病发作之前阻止它。
Nature. 2017 Jul 12;547(7662):153-155. doi: 10.1038/547153a.

引用本文的文献

1
Preclinical Alzheimer's dementia: a useful concept or another dead end?临床前阿尔茨海默病性痴呆：一个有用的概念还是另一个死胡同？
Eur J Ageing. 2022 Oct 19;19(4):997-1004. doi: 10.1007/s10433-022-00735-w. eCollection 2022 Dec.
2
Study partners: essential collaborators in discovering treatments for Alzheimer's disease.研究伙伴：发现阿尔茨海默病治疗方法的重要合作者。
Alzheimers Res Ther. 2018 Sep 27;10(1):101. doi: 10.1186/s13195-018-0425-4.
3
Measuring cognition and function in the preclinical stage of Alzheimer's disease.在阿尔茨海默病临床前阶段测量认知与功能。
Alzheimers Dement (N Y). 2018 Feb 13;4:64-75. doi: 10.1016/j.trci.2018.01.003. eCollection 2018.
4
Study partners should be required in preclinical Alzheimer's disease trials.临床前阿尔茨海默病试验应要求有研究伙伴。
Alzheimers Res Ther. 2017 Dec 6;9(1):93. doi: 10.1186/s13195-017-0327-x.

本文引用的文献

1
Measuring the Value of Prescription Drugs.衡量处方药的价值。
N Engl J Med. 2015 Dec 31;373(27):2595-7. doi: 10.1056/NEJMp1512009. Epub 2015 Nov 18.
2
Modeling test and treatment strategies for presymptomatic Alzheimer disease.无症状性阿尔茨海默病的建模测试与治疗策略
PLoS One. 2014 Dec 4;9(12):e114339. doi: 10.1371/journal.pone.0114339. eCollection 2014.
3
Researchers test strategies to prevent Alzheimer disease.研究人员测试预防阿尔茨海默病的策略。
JAMA. 2014;311(16):1596-8. doi: 10.1001/jama.2014.3891.
4
Monetary costs of dementia in the United States.美国痴呆症的货币成本。
N Engl J Med. 2013 Apr 4;368(14):1326-34. doi: 10.1056/NEJMsa1204629.
5
Regulatory innovation and drug development for early-stage Alzheimer's disease.早期阿尔茨海默病的监管创新与药物研发
N Engl J Med. 2013 Mar 28;368(13):1169-71. doi: 10.1056/NEJMp1302513. Epub 2013 Mar 13.
6
Decision analytic models for Alzheimer's disease: state of the art and future directions.阿尔茨海默病的决策分析模型：现状与未来方向
Alzheimers Dement. 2008 May;4(3):212-22. doi: 10.1016/j.jalz.2008.02.003.
7
Functional deficits in patients with mild cognitive impairment: prediction of AD.轻度认知障碍患者的功能缺陷：阿尔茨海默病的预测
Neurology. 2002 Mar 12;58(5):758-64. doi: 10.1212/wnl.58.5.758.

Unfinished Business in Preventing Alzheimer Disease.

作者信息

Karlawish Jason, Langa Kenneth M

机构信息

Perelman School of Medicine, Departments of Medicine, Medical Ethics and Health Policy, and Neurology, Penn Program for Precision Medicine for the Brain, University of Pennsylvania, Philadelphia.

Institute for Social Research, Institute for Healthcare Policy and Innovation, Department of Internal Medicine, University of Michigan, Ann Arbor3Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, Michigan.

出版信息

JAMA Intern Med. 2016 Dec 1;176(12):1739-1740. doi: 10.1001/jamainternmed.2016.6310.

DOI:10.1001/jamainternmed.2016.6310
PMID:27749947
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5458728/
Abstract
摘要